Steady-state pharmacokinetics, efficacy, and safety of bictegravir in Chinese patients with HIV: an observational study [0.03%]
bictegravir在中国HIV患者中的稳态药代动力学、疗效和安全性观察性研究结果
Ran Xiao,Qiang Fu,Ling Chen et al.
Ran Xiao et al.
Background: This study aimed to evaluate the steady-state plasma concentration, efficacy, and safety of bictegravir (BIC) in Chinese people with HIV (PWH) receiving BIC-based therapy for at least 6 months. ...
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs [0.03%]
从分子到意义：揭秘迷幻药物的抗抑郁机制
Acero Vp,Flatt Ta,Gooch Pm et al.
Acero Vp et al.
Introduction: Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in the context of psychotherapy - a stark contrast to traditio...
COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes [0.03%]
联合用药优于单一疗法：改善2型糖尿病患者血糖不达标现状的治疗策略
Djordje S Popovic,Dimitrios Patoulias,Theocharis Koufakis et al.
Djordje S Popovic et al.
During treatment intensification to injectable therapies among persons with type 2 diabetes mellitus (T2DM) without evidence of severe insulin deficiency, a glucagon-like peptide-1 agonist (GLP-1 RA) is preferred to insulin. However, due to...
Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up [0.03%]
戈利木单抗治疗银屑病关节炎和轴性脊柱关节炎患者的长期疗效：长达十年随访的证据
Paula Alvarez,Arancha Gómez-Cosme,Pablo González Del Pozo et al.
Paula Alvarez et al.
Background: While there are relatively large number of studies on the retention of biologics in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), very long-term retention studies are scarce. ...
Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis [0.03%]
基于生理的药代动力学模型预测阿达木单抗在儿童关节炎患者中的暴露量及给药剂量
Ya-Xin Liu,Li-Ying Gong,Jin-Long Liu et al.
Ya-Xin Liu et al.
Background: Adalimumab has been approved for treating juvenile idiopathic arthritis (JIA). This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model for adalimumab in JIA patients to optimize person...
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system [0.03%]
大型医疗体系中肿瘤临床实践中采用生物仿制药的实际挑战和考虑因素
Mansoor A Khan,Laila Carolina Abu Esba,Consuela Cheriece Yousef et al.
Mansoor A Khan et al.
Introduction: Biosimilars have the potential to offer cost savings with comparable efficacy and safety to innovator products and, thus, increase access to treatment for more patients. However, there were significant chall...
A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms [0.03%]
氟唑平治疗绝经过渡期和绝经后妇女血管舒缩症状的安全性和有效性的评价:2项双盲、安慰剂对照试验的汇总分析
Laura Cucinella,Chiara Cassani,Sara Tedeschi et al.
Laura Cucinella et al.
Introduction: Fezolinetant is a first-in-class non-hormonal pharmacological treatment recently approved for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Its mechanism of action selectively target...
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis [0.03%]
抑制胃酸药物对血管内皮生长因子受体酪氨酸激酶抑制剂疗效的影响：系统评价和meta分析证据
Jiefeng Luo,Qiong Du,Jiyong Liu
Jiefeng Luo
Background: This meta-analysis evaluated theprevalence of gastric acid suppressants (GASs) in patients receiving vascularendothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) andexplored drug-drug int...
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis [0.03%]
添加喹硫平或奥氮平对度洛西汀代谢的影响：一项回顾性分析
Nele Römer,Arnim Johannes Gaebler,Irene Neuner et al.
Nele Römer et al.
Background: In antidepressant augmentation strategies, olanzapine or quetiapine are often concomitantly administered to duloxetine. The use of the same enzymes for the degradation of the drugs may lead to clinically relev...
Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis [0.03%]
多发性硬化症儿童和青少年疾病修饰治疗的可用性和使用情况的范围审查
Lauren Strasser,Beyza Ciftci,Joley Johnstone et al.
Lauren Strasser et al.
Introduction: Approximately 10% of individuals with multiple sclerosis (MS) have pediatric-onset ( 10 DMT exposed pediatric-MS patients with full-text available in English. RCTs/pharmaceutical-industry funded studies were...